Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Ofatumumab retreatment and mai...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
Bibliographic Details
Main Authors:
Osterborg, A
,
Dyer, M
,
Mayer, J
,
Hess, G
,
Hillmen, P
,
Schetelig, J
,
Schuh, A
,
Smolej, L
,
Beck, C
,
Dreyfus, B
,
Hellman, A
,
Kozlowski, P
,
Pfreundschuh, M
,
Rizzi, R
,
Spacek, M
,
Chan, G
,
Gupta, I
,
Phillips, J
,
Lisby, S
,
Wierda, W
Format:
Conference item
Published:
2012
Holdings
Description
Similar Items
Staff View
Similar Items
UK experience of Ofatumumab in refractory B-CLL
by: Varghese, A, et al.
Published: (2011)
Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)
A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)
Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)
Do not treat all CLL patients with fludarabine
by: Bosanquet, A, et al.
Published: (1998)